Injective CEO Eric Chen expects a US spot ETF tied to INJ to launch before 2027, stating that the 2027 timeline is "a bit too far out." Speaking at Korea Blockchain Week, Chen declined to provide specific timing for the potential product launch. Asset managers 21Shares and Canary have already filed INJ ETF applications with the SEC, signaling growing institutional interest in the Layer-1 blockchain token. The pending filings mark a significant step toward broader regulated access for Injective in the US market.